![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodie... Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes on developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.01 | -0.387596899225 | 2.58 | 2.81 | 2.44 | 596287 | 2.60627674 | CS |
4 | 0.44 | 20.6572769953 | 2.13 | 2.81 | 2 | 480665 | 2.44452706 | CS |
12 | 1.09 | 73.6486486486 | 1.48 | 2.81 | 1.47 | 416309 | 2.07254943 | CS |
26 | 0.82 | 46.8571428571 | 1.75 | 2.81 | 1.38 | 439034 | 1.9755353 | CS |
52 | -0.59 | -18.6708860759 | 3.16 | 3.62 | 1.3 | 502946 | 2.09968689 | CS |
156 | -24.63 | -90.5514705882 | 27.2 | 46.4 | 1.3 | 555065 | 14.83180119 | CS |
260 | -23.43 | -90.1153846154 | 26 | 53.762 | 1.3 | 624518 | 21.42742852 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions